Recombinant Human TIGIT protein (His Tag)

种属

Human

纯度

>95 %, SDS-PAGE

标签

His Tag

生物活性

EC50: 100-400 ng/mL

Cat no : Eg0749

Print datasheet

Synonyms

TIGIT, T-cell immunoreceptor with Ig and ITIM domains, VSIG9, VSTM3



产品信息

纯度 >95 %, SDS-PAGE
内毒素 <0.1 EU/μg protein, LAL method
生物活性 Immobilized Human TIGIT (His tag) at 2 μg/mL (100 μL/well) can bind Human CD155 (hFc tag, Myc tag, His tag) with a linear range of 100-400 ng/mL.
来源 HEK293-derived Human TIGIT protein Met22-Pro141 (Accession# Q495A1-1) with a His tag at the C-terminus.
基因ID 201633
蛋白编号 Q495A1-1
预测分子量 13.9 kDa
SDS-PAGE 15-18 kDa, reducing (R) conditions
组分 Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
复溶 Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
储存条件
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
运输条件 The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

背景信息

T cell immunoreceptor with Ig and ITIM domains(TIGIT), also named as V-set and immunoglobulin domain-containing protein 9 (VSIG9), V-set and transmembrane do-maincontaining protein 3 (VSTM3) and Washington University cell adhesion molecule (WUCAM), is a co-inhibitory molecule belonging to the immunoglobulin superfamily that was first discovered in 2009. It consists of an extracellular immunoglobulin variable (IgV) domain, a type I transmembrane domain and an intracellular domain with an immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoglobulin tail tyrosine (ITT)-like motif. TIGIT is an inhibitory receptor expressed on several types of lymphocytes. Efficacy of antibody blockade of TIGIT in cancer immunotherapy is currently widely being investigated in both pre-clinical and clinical studies. In multiple cancers TIGIT is expressed on tumor-infiltrating cytotoxic T cells, helper T cells, regulatory T cells and NK cells, and its main ligand CD155 is expressed on tumor-infiltrating myeloid cells and upregulated on cancer cells, which contributes to local suppression of immune-surveillance.

参考文献:

1.Qiu D, et al. (2022) Clin Exp Med Jun;23(2):165-174. 2.Boles KS, et al. (2009) Eur J Immunol 39(3):695–703. 3.Levin SD, et al. (2011) Eur J Immunol 41(4):902–15. 4.Harjunpää H, et al. (2020) Clin Exp Immunol 200(2):108–19. 5.Jin S, et al. (2022) Front. Oncol. Dec 20;12:1091782. 6.Ge Z, et al. (2021) Front. Immunol. Jul 22;12:699895.